---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-399416"
form_type: "8-K"
ticker: "SRPT"
cik: "0000873303"
company_name: "Sarepta Therapeutics, Inc."
filed_at: "2026-09-23T20:13:57+00:00"
generated_at: "2026-09-23T20:15:23.597224+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sarepta settles patent litigations with REGENXBIO and UPenn for $39M

## Summary
- Sarepta to pay REGENXBIO $39.0M lump sum within 10 days to settle patent disputes over AAVrh74 capsid and ELEVIDYS.
- Settlement resolves infringement claims involving U.S. Patents 11,680,274 and 10,526,617; releases Sarepta and Catalent from past claims.
- Parties agree to dismiss pending litigations with prejudice; no admission of liability; each bears own costs.
- Company had recorded $39.0M litigation contingency charge in Q2 2026 related to anticipated settlement.

## SEC filing metadata
- accession: 0001193125-26-399416
- form_type: 8-K
- ticker: SRPT
- cik: 0000873303
- company_name: Sarepta Therapeutics, Inc.
- filed_at: 2026-09-23T20:13:57+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/873303/000119312526399416/0001193125-26-399416-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/873303/000119312526399416/srpt-20260923.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-399416
- JSON: https://secwatch.observer/filing/0001193125-26-399416.json
- Plain text: https://secwatch.observer/filing/0001193125-26-399416.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.